Search results

  1. Twin and triplet pregnancy (NG137)

    This guideline covers the care that should be offered to women with a twin or triplet pregnancy in addition to the routine care that is offered to all women during pregnancy. It aims to reduce the risk of complications and improve outcomes for women and their babies.

  2. Sodium zirconium cyclosilicate for treating hyperkalaemia (TA599)

    Evidence-based recommendations on sodium zirconium cyclosilicate (Lokelma) for treating hyperkalaemia in adults

  3. Caesarean section (CG132)

    This guideline covers when to offer caesarean section, procedural aspects of the operation and care after caesarean section. It aims to improve the consistency and quality of care for women who are considering a caesarean section or have had a caesarean section in the past and are now pregnant again.

  4. Benralizumab for treating severe eosinophilic asthma (TA565)

    Evidence-based recommendations on benralizumab (Fasenra) for treating severe eosinophilic asthma (SEA; elevated levels of eosinophils in blood) in adults

  5. Fertility

    Everything NICE has said on assessing and treating people with fertility problems in an interactive flowchart

  6. Caesarean section

    Everything NICE has said on caesarean section in an interactive flowchart

  7. Trauma

    Everything NICE has said on assessing and managing trauma in an interactive flowchart

  8. Hypertension in adults: diagnosis and management (NG136)

    This guideline covers identifying and treating primary hypertension (high blood pressure) in people aged 18 and over, including people with type 2 diabetes. It aims to reduce the risk of cardiovascular problems such as heart attacks and strokes by helping healthcare professionals to diagnose hypertension accurately and treat it effectively.

  9. Type 2 diabetes in adults: management (NG28)

    This guideline covers the care and management of type 2 diabetes in adults (aged 18 and over). It focuses on patient education, dietary advice, managing cardiovascular risk, managing blood glucose levels, and identifying and managing long-term complications.

  10. Health of people in the criminal justice system

    Everything NICE has said on managing the physical and mental health of people in prison, and the mental health of people in the criminal justice system

  11. Olaparib for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy (TA598)

    Evidence-based recommendations on olaparib (Lynparza) for treating BRCA mutation-positive, advanced ovarian, fallopian tube or primary peritoneal cancer that

  12. Behaviour change

    Everything NICE has said on changing people's health-related behaviours, including interventions aimed at over 16s, in an interactive flowchart

  13. Osteoporosis

    Everything NICE has said on assessing the risk of, preventing and treating osteoporotic fragility fractures in adults in an interactive flowchart

  14. Psoriasis

    Everything NICE has said on psoriasis in an interactive flowchart

  15. Obesity

    Everything NICE has said on preventing, identifying, assessing and managing obesity in an interactive flowchart

  16. A national evaluation of early pregnancy assessment unit service provision should be carried out to identify factors affecting outcomes. Factors should include whether care is provided in a dedicated unit, staffing configuration and opening hours of dedicated services. Outcomes should include both process (service) outcomes and pregnancy-related outcomes. Data collected should be used to analyse the cost effectiveness of early pregnancy assessment units compared with other models of care.

    Recommendation ID NG126/1 Question A national evaluation of early pregnancy assessment unit service provision should be carried out to

  17. Psychosis and schizophrenia

    Everything NICE has said on recognising and managing psychosis and schizophrenia in children, young people and adults in an interactive flowchart

  18. Endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms (IPG658)

    Evidence-based recommendations on endovascular insertion of an intrasaccular wire-mesh blood-flow disruption device for intracranial aneurysms in adults. This

  19. Ribociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (TA593)

    Evidence-based recommendations on ribociclib (Kisqali) for hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative, locally advanced

  20. Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer (TA595)

    Evidence-based recommendations on dacomitinib (Vizimpro) for untreated locally advanced or metastatic epidermal growth factor receptor (EGFR) mutation-positive

  21. Patisiran for treating hereditary transthyretin amyloidosis (HST10)

    Evidence-based recommendations on patisiran (Onpattro) for treating hereditary transthyretin amyloidosis in adults with stage 1 and stage 2 polyneuropathy

  22. Venous thromboembolism in over 16s: reducing the risk of hospital-acquired deep vein thrombosis or pulmonary embolism (NG89)

    This guideline covers assessing and reducing the risk of venous thromboembolism (VTE or blood clots) and deep vein thrombosis (DVT) in people aged 16 and over in hospital. It aims to help healthcare professionals identify people most at risk and describes interventions that can be used to reduce the risk of VTE.

  23. Blood and bone marrow cancers

    Everything NICE has said on blood and bone marrow cancers including leukaemia in an interactive flowchart

  24. Alcohol interventions in secondary and further education (NG135)

    This guideline covers interventions in secondary and further education to prevent and reduce alcohol use among children and young people aged 11 up to and including 18. It also covers people aged 11 to 25 with special educational needs or disabilities in full-time education. It will also be relevant to children aged 11 in year 6 of primary school.